The Asia Pacific heart valve device market will experience robust growth through 2027, driven by economic expansion, an aging population, and the launch and adoption of new THV devices.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for heart valve devices in Asia Pacific across a 10-year period.
Adoption of THV—particularly TAVR—will drive growth of the Asia Pacific heart valve device market.
What factors are driving adoption of TAVR in Asia Pacific? Do they vary by country?
How much does the high cost of TAVR impact adoption in the Asia Pacific region?
What types of patients will be eligible for these procedures?
Who are the local competitors in this market?
What other THV products are under development?
Due to cost-sensitive nature of Asia Pacific countries, companies will need to have different strategies to succeed in the heart valve device market.
What strategies are companies using to enter and increase their market share in the Asia Pacific heart valve device market?
How will these strategies differ between countries within the Asia Pacific market?
Who are the major players in this space?
The disease epidemiology of those in the Asia Pacific region differs from that of Western countries.
How will these differences affect the choice between tissue and mechanical heart valves?
Which heart valves are most likely to be replaced or repaired in the Asia Pacific region?
How does disease epidemiology vary among the Asia Pacific countries?
Surgical heart valve replacement and surgical annuloplasty repair devices face increasing competition from THV devices.
How will new THV device technologies affect the surgical repair and replacement device markets?
When are TMVI devices expected to enter the Asia Pacific market? Which company is most likely to enter first?
When are TMVR devices expected to enter China, and South Korean Markets?
- Heart Valve Devices - Market Insights - Asia Pacific
Author(s): Shruthi Narendranath, MSc
Shruthi Narendranath is an analyst within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in heart valve and periphral vascular device markets. Shruthi holds a Master's degree in Bioinformatics from Cardiff University.